Measurement of gluconeogenesis and intermediary metabolism using stable isotopes
View Patent ↗The present invention provides a combination of carbon-13 and deuterium metabolic tracers and methods that when used in conjunction with nuclear magnetic resonance spectroscopy, provide a measurement of metabolic fluxes in the target organisms. The tracers of the present invention may be taken orally during the same clinical exam. The metabolic information can be derived from blood, urine or other fluids to provide a comprehensive profile of glucogenic metabolism. The subject matter of the present invention may be applied to the study of metabolic dysfunction related to obesity, diabetes, HIV infection and a variety of other disease conditions.
1. A method for preparing a tracer composition comprising:
obtaining a 13 C labeled Krebs cycle metabolite precursor that will produce an analyte; and
obtaining a deuterium source,
wherein gluconeogenesis is measured from a subject that was provided the precursor and the deuterium source, and produced the analyte, by comparison of relative nuclear magnetic resonance signal areas in a spectrum obtained from labeled components in the analyte.
2. The method of claim 1 , wherein the analyte is 13 C-glucose.
3. The method of claim 1 , wherein the precursor is glucose, lactose, lactate or alanine.
4. The method of claim 1 , wherein the deuterium source is deuterated water.
5. The method of claim 1 , wherein the analyte is glucose deuterated in the 2, 5 and 6S positions, and any transformation in glucose that maintains the 2,5 and 6 positions in relation to one another.
6. The method of claim 1 , wherein the analyte is (1-6 13 C 2 )-glucose.
7. The method of claim 4 , wherein the deuterated water is D 2 O.
8. The method of claim 1 , wherein nuclear magnetic resonance profiles are used to measure flux selected from the group consisting of pyruvate recycling, anaplerotic, gluconeogenic, and combinations thereof.
9. The method of claim 1 , wherein the analyte is 13 C-labeled glucose with the label at the 2 or 5 positions, or at both positions.
10. The method of claim 9 , wherein the metabolite is a transformation of the labeled glucose containing the labeled 2 position, or the labeled 5 position, or both.
11. The method of claim 1 , further comprising the step of adding [ 13 C 3 ] propionate.
12. The method of claim 1 , wherein the Krebs cycle precursor is selected from the group consisting of pyruvic acid, acetic acid, acetoacetic acid and beta-hydroxybutyric acid.
13. The method of claim 1 , wherein the analyte is selected from the group consisting of pyruvic acid, acetic acid citric acid, isocitric acid, cis-aconitic acid, 2-ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.
14. A method for preparing a tracer composition comprising:
obtaining a deuterium source,
wherein gluconeogenesis is measured from a subject that was provided the deuterium source, and produced an analyte, by comparison of the relative nuclear magnetic resonance signal areas in a spectrum obtained from deuterium components in the analyte, wherein the analyte is selected from the group consisting of glucose deuterated in the 2, 5 and 6 positions and deuterated glucose with any transformation that maintains the 2,5 and 6 positions in relation to one another.
15. A method for preparing a tracer composition comprising:
obtaining a deuterium source,
wherein gluconeogenesis is measured from a subject that was provided the deuterium source, and produced an analyte, by comparison of the relative nuclear magnetic resonance signal areas in a spectrum obtained from deuterium components in the analyte, wherein the analyte is (1-6 13 C 2 ).glucose.
16. The method of claim 14 , wherein nuclear magnetic resonance profiles are used to measure flux selected from the group consisting of pyruvate recycling, anaplerotic, gluconeogenic, and combinations thereof.
17. A method for preparing a tracer composition comprising:
obtaining a deuterium source;
wherein gluconeogenesis is measured from a subject that was provided the deuterium source, and produced an analyte, by comparison of the relative nuclear magnetic resonance signal areas in a spectrum obtained from deuterium components in the analyte, wherein the analyte is selected from the group consisting of pyruvic acid, acetic acid citric acid, isocitric acid, cis-aconitic acid, 2-ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.
18. A method for preparing an isotopic metabolic flux tracer composition comprising:
providing a 13 C labeled Krebs cycle metabolite precursor to a subject to produce an analyte;
obtaining a sample from the subject; and
measuring nuclear magnetic resonance signals of the sample to determine the rate of gluconeogenesis.
19. The method of claim 18 , wherein the analyte is 13 C-glucose.
20. The method of claim 18 , wherein the analyte is glucose labeled with 13 C at positions 1 through 6, or combinations of two or more at any position.
21. The method of claim 18 , wherein the analyte is (1-6 3 C 2 )-glucose.
22. The method of claim 18 , wherein the sample is from blood, urine or tissue extracts.
23. The method of claim 18 , further comprising the step of providing the subject with [ 13 C 3 ] propionate.
24. The method of claim 18 , wherein the Krebs cycle precursor is selected from the group consisting of pyruvic acid, acetic acid, acetoacetic acid, beta-hydroxybutyric acid.
25. The method of claim 18 , wherein the analyte is selected from the group consisting of pyruvic acid, acetic acid citric acid, isocitric acid, cis-aconitic acid, 2-ketoglutaric acid, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and mixtures thereof.
26. The method of claim 18 , wherein the 13 C Krebs cycle precursor is provided orally.
27. A method for preparing a tracer composition comprising:
obtaining a deuterium source;
wherein gluconeogenesis is measured from a subject that was provided the deuterium source, and produced an analyte, by comparison of the relative nuclear magnetic resonance signal areas in a spectrum obtained from deuterium components in the analyte, and
wherein the analyte is glucose deuterated in the 2, 5 and 6 positions, and any transformation of glucose that maintains the 2,5 and 6 positions in relation to one another, and
wherein the analyte is produced in the blood, urine or tissue.
28. The method of claim 1 , wherein the analyte is produced in the blood, urine or tissue.
29. A method for preparing an isotopic metabolic flux tracer composition comprising:
providing a 13 C labeled Krebs cycle metabolite precursor to a subject to produce an analyte;
obtaining a sample from the subject; and
measuring nuclear magnetic resonance of labeled tracers in the sample to determine the rate of gluconeogenesis,
wherein the analyte is 13 C-glucose.
30. The method of claim 15 , wherein nuclear magnetic resonance profiles are used to measure flux selected from the group consisting of pyruvate recycling, anaplerotic, gluconeogenic, and combinations thereof.
31. The method of claim 17 , wherein nuclear magnetic resonance profiles are used to measure flux selected from the group consisting of pyruvate recycling, anaplerotic, gluconeogenic, and combinations thereof.